Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV
NCT03008213 · Joseph Ma · PHASE2 · terminated · last registry update 2019-12-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI is leaving UCSD” | – | Registry record, Joseph Ma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR3A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-07Results posted on the registry: Helsinn Healthcare SA, Netupitant + Palonosetron (NCT03204279)
- 2020-10-28Phase 3 first posted: Jennifer Holder-Murray, Neuraxial Analgesia + Regional Block 1: Paravertebral (NCT04606264)
- 2020-08-07Phase 3 first posted: University of Michigan Rogel Cancer Center, Ondansetron + Dexamethasone (NCT04503668)
- 2019-10-30Phase 3 first posted: University of Saskatchewan, Acetaminophen, Gabapentin + Acetaminophen, Gabapentin (NCT04144933)
- 2019-09-24Phase 3 first posted: Adial Pharmaceuticals, AD04 (ondansetron) + Matching placebo (NCT04101227)
- 2019-05-08Phase 3 first posted: Leiden University Medical Center, Rituximab + endoxan (NCT03942887)
- 2019-02-22Phase 3 first posted: University of Calgary, Ondansetron Oral Solution + Oral Placebo (NCT03851835)
- 2019-01-28Phase 3 first posted: University of Colorado, Denver, Granisetron + Ondansetron (NCT03817970)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision